In this episode (24:48 min), Medicom’s correspondent covers 6 presentations from ECTRIMS held in Amsterdam, the Netherlands, from 26-28 October 2022, with an extra interview one of the speakers, Dr Ilse Nauta, from the Free University in Amsterdam, the Netherlands.
- MS associated with a broader Epstein-Barr virus specific, T-cell receptor repertoire
New research suggests that not only is MS preceded by Epstein-Barr virus (EBV) infection, but it is also associated with a broader EBV-specific T-cell receptor (TCR) repertoire. This is consistent with the assumption that there is an ongoing aberrant immune response to EBV in MS patients. Alternatively, it could be the remnant of a disease-triggering event or an ongoing CD8 immune response to EBV. - Cognitive rehab and mindfulness reduce cognitive complaints in MS
In a randomised-controlled trial, cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) had short-term positive effects on cognitive complaints in MS patients. In the long term, CRT helped to improve personalised cognitive goals and MBCT processing speed. - Ravulizumab significantly reduces relapses in AQP4+ NMOSD
Treatment with ravulizumab was highly effective in reducing the risk of relapse in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD). No relapses were observed over a median follow-up of 73.5 weeks in the open-label, phase 3, externally-controlled CHAMPION-NMOSD trial of ravulizumab. - Dimethyl fumarate reduces risk of a first clinical event in RIS
For the first time, a randomised, placebo-controlled trial demonstrated beneficial effects of a disease-modifying therapy (DMT) in preventing a first acute clinical event in people with a radiologically isolated syndrome (RIS). In the ARISE trial, dimethyl fumarate reduced this risk by over 80%. - New data on the safety of anti-CD20 mAbs around pregnancy
A new study suggests B-cell depleting anti-CD20 monoclonal antibodies (mAbs) such as ocrelizumab may be safe when used before or during the first trimester of pregnancy and/or during lactation. Anti-CD20 mAbs do not seem to have a depleting effect on the physiological B-cell development in exposed infants. Exposure in the second or third trimester can lead to B-cell depletion. - Autologous hematopoietic stem cell transplantation versus DMTs
From observational, single-arm cohorts, autologous hematopoietic stem cell transplantation (AHSCT) is known to be highly efficacious in MS patients with highly active disease. Results of a new study comparing AHSCT to various highly efficacious, disease-modifying therapies (DMTs) reveal it to be superior to fingolimod and comparable with ocrelizumab and natalizumab therapy in the prevention of relapses.
Enjoy listening!
Posted on
Previous Article
« Letter from the Editor Next Article
A Novel Microbiome Signature in Gastric Cancer »
« Letter from the Editor Next Article
A Novel Microbiome Signature in Gastric Cancer »
Table of Contents: ECTRIMS 2022
Featured articles
Letter from the Editor
Diagnosis and Prediction of Disease Course
A case for including optic nerve lesions in the McDonald criteria
Cerebrospinal fluid kappa-free light chains for MS diagnosis
Early, non-disabling relapses increase disability accumulation
Physical impairment is present before perceived MS onset
Chronic active MS lesions respond poorly to anti-CD20 antibodies
Treatment: Trials & Strategies
Dimethyl fumarate reduces the risk of a first clinical event in RIS
How and when to make a timely switch to high-efficacy DMT
Comparing real-world effectiveness of DMTs
Study fails to show non-inferiority of rituximab to ocrelizumab
Autologous haematopoietic stem cell transplantation versus DMTs
Progressive MS
Stem cell transplantation not superior to natalizumab in progressive MS
Efficacy of DMTs fades away in secondary progressive MS
Smartphone tapping can help detect progressive MS
Paediatric MS
Early treatment with DMT effective in paediatric-onset MS
Fingolimod in paediatric MS: results of up to 6 years
Switching treatment after initial platform injectable DMT: real-world data
Pregnancy
Pregnancy and infant outcomes in women receiving ocrelizumab
New safety data of anti-CD20 mAbs around pregnancy
MS activity and pregnancy outcomes after long-term use of natalizumab
NMOSD
Ravulizumab significantly reduced relapses in AQP4+ NMOSD
NMOSD patients are cognitively impaired regardless of serostatus
Evidence-based consensus on pregnancy in NMOSD
COVID-19
COVID-19 and MS: lessons learned thus far
Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes
Humoral and cellular immune responses after SARS-CoV-2 vaccination
Miscellaneous
Re-myelination strategies in MS still pose many unanswered questions
MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire
Cognitive rehab and mindfulness reduce cognitive complaints in MS
Related Articles
November 8, 2019
Genes, environment, and safety monitoring in using registries
November 25, 2020
NG-specific biomarkers differentiate NMOSD from MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com